OOIR: Observatory of International Research

Papers

(The H4-Index of Cancer Immunology Research is 35. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
A Sampling of Highlights from the Literature	112
Abstract A022: Therapeutic inhibition of TREX1 elicits type I interferon–mediated antitumor immunity with minimal autoimmune toxicity	106
Abstract A018: Targeting PTPN1/PTPN2 with KQ-791 enhances NK cell cytotoxicity during tumor rechallenge	94
Abstract B002: Meta-Analysis of Neoantigens: Insights from the Cancer Epitope Database and Analysis Resource (CEDAR)	87
Abstract PR-10: Leveraging peripheral leukocyte recruitment to improve efficacy and mitigate toxicities following checkpoint blockade	76
Host Interactions with Engineered T-cell Micropharmacies	75
Exercise as an Immune Boost: Mechanism-Driven Support for Lifestyle Interventions	74
Correction: Inflammation Mediated by Gut Microbiome Promotes Immune Suppression and Lung Adenocarcinoma Progression	64
Self-Renewing CD8+ T-cell Abundance in Blood Associates with Response to Immunotherapy	63
Abstract LB-C008: Replication stress coupled to cGAS–STING activation defines an innate immune–inflamed transcriptional state in head and neck squamous cell carcinoma that Is enriched for HPV-positive	60
Abstract LB-C012: Immune-Like Circulating Tumor Cells and Large Extracellular Vesicles in Metastatic Breast Cancer	57
Abstract LB-A013: Tuning TCR immunotherapy targeting prostatic acid phosphatase via catch bond modifications for advanced prostate cancer	56
Abstract LB-A006: Impact of pharmacokinetic profiles on the in vivo antitumor efficacy of EHMT2 inhibitors combined with immune checkpoint blockade	55
Abstract LB-C011: Using Organoids and Tumor Infiltrating Lymphocytes to Elucidate the ”Dark Matter” of Human Tumor Antigens	55
Abstract A046: Dendritic cell dysfunction predicts adverse prognosis in high-risk acute lymphoblastic leukemia	54
Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer	54
Abstract A028: Combination therapy with a TCR Vβ-directed bifunctional molecule, cisplatin and anti-PD-1 promotes antitumor activity in immune checkpoint blockade-refractory head and neck murine tumor	52
Abstract A041: LAG-3 is associated with poor prognosis and LAG-3 blockade enhances the efficacy of PD-1 blockade combined with radiation therapy in breast cancer	52
Abstract C070: Targeting neoantigens conserved across organs and species overcomes tumor immune escape	49
Single-Cell Analysis of Posttranslational Modifications Identifies Immunosuppressive Macrophage Subtypes in the HBV-Positive Hepatocellular Carcinoma Microenvironment	48
Abstract B035: Antibody-lectin chimeras for glyco-immune checkpoint blockade	48
Reciprocal Interactions Between the Gut Microbiome and Mammary Tissue Mast Cells Promote Metastatic Dissemination of HR+ Breast Tumors	46
Optimal Neoantigen Cancer Vaccines Target CD8+ and CD4+ T Cells with Multiple Antigens	46
Combination Therapy Approaches to Enhance the Efficacy of ERV-Targeting Vaccines in Cancer	45
IL-15 Complex Enhances Agonistic Anti-CD40 + Anti-PDL1 by Correcting the T-bet to Tox Ratio in CD8+ T cells Infiltrating Pancreatic Ductal Adenocarcinoma	45

Transforming the Dark into Light: A Siglec-9 Switch	44
CLN-617 Retains IL2 and IL12 in Injected Tumors to Drive Robust and Systemic Immune-Mediated Antitumor Activity	44
A Population of TIM4+FOLR2+ Macrophages Localized in Tertiary Lymphoid Structures Correlates to an Active Immune Infiltrate Across Several Cancer Types	43
The ω-3 Polyunsaturated Fatty Acid Docosahexaenoic Acid Enhances NK-Cell Antitumor Effector Functions	43
Preclinical Characterization and Phase I Study of an Anti–HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies	40
IL18 at the Crossroads between Chronic Inflammation and T-cell Exhaustion in Pancreatic Cancer	39
Topical resiquimod elicits systemic protection and improves anti-PD1 therapy in melanoma via priming of CD8+ T cells	38
T-cell Senescence in the Tumor Microenvironment	37
Engineering CD20 CARs with a Twist	36
A Sampling of Highlights from the Literature	36
Profiling Multiple CD8+ T-cell Functional Dimensions Enhances Breast Cancer Immune Assessment	35
A Sampling of Highlights from the Literature	35
Harnessing Microbiota to Improve Immunotherapy for Gastrointestinal Cancers	35
Circulating Neoantigen- and Viral Oncoprotein–Specific CD8+ T Cells Share a Transcriptional Signature	35